Evommune, Inc. (NYSE:EVMN) Given Consensus Recommendation of “Buy” by Analysts

Evommune, Inc. (NYSE:EVMN) has been assigned a consensus recommendation of “Buy” from the fourteen research firms that are currently covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, one has given a hold recommendation, nine have assigned a buy recommendation and three have given a strong buy recommendation to the company. The average 12-month price target among analysts that have updated their coverage on the stock in the last year is $49.25.

Several equities analysts have issued reports on the stock. Royal Bank Of Canada restated an “outperform” rating and set a $48.00 target price on shares of Evommune in a research note on Friday, April 10th. Evercore reissued an “outperform” rating and issued a $55.00 target price on shares of Evommune in a report on Tuesday, February 10th. Wall Street Zen raised shares of Evommune from a “sell” rating to a “hold” rating in a report on Sunday, May 10th. Oppenheimer initiated coverage on shares of Evommune in a report on Tuesday, April 7th. They set an “outperform” rating and a $50.00 price objective for the company. Finally, Stifel Nicolaus initiated coverage on shares of Evommune in a report on Friday, May 1st. They set a “buy” rating and a $54.00 price objective for the company.

Evommune Stock Down 0.6%

Shares of EVMN stock opened at $22.74 on Monday. Evommune has a one year low of $13.89 and a one year high of $33.20. The company’s 50-day moving average price is $24.19. The stock has a market cap of $818.95 million and a P/E ratio of -2.39.

Evommune (NYSE:EVMN) last announced its quarterly earnings data on Thursday, May 7th. The company reported ($0.64) EPS for the quarter, beating the consensus estimate of ($0.83) by $0.19. As a group, analysts anticipate that Evommune will post -2.86 EPS for the current year.

Hedge Funds Weigh In On Evommune

Institutional investors have recently bought and sold shares of the stock. Capricorn Fund Managers Ltd purchased a new position in Evommune during the fourth quarter valued at $1,027,000. Janus Henderson Group PLC purchased a new position in Evommune during the first quarter valued at $20,615,000. Eversept Partners LP purchased a new position in Evommune during the first quarter valued at $1,257,000. Strs Ohio purchased a new position in Evommune during the first quarter valued at $41,000. Finally, Sofinnova Investments Inc. purchased a new position in Evommune during the fourth quarter valued at $2,625,000.

About Evommune

Evommune is a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria (“CSU”), atopic dermatitis (“AD”) and ulcerative colitis (“UC”). Chronic inflammation is a significant healthcare problem in the world, substantially impacting patients’ quality of life and leading to life-threatening conditions. These conditions, if not prevented, ultimately lead to fatal diseases, such as cardiovascular diseases, diabetes and cancer, which contribute to three out of every five deaths worldwide and result in an estimated $90 billion of annual cost to the healthcare system in the United States.